Axial Therapeutics Raises $37.25 Million In Series C Financing To Advance Its Pipeline Of Gut-Targeted Small Molecule Drugs For Neurological Diseases And Disorders
Amount Raised
$37.3 Million
Round Type
Series C
WoburnBiotechnologyHealthcareHealth CareDescription
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, Australia, and the University of Tokyo Innovation Platform Company (UTokyo IPC) led the round as new investors, joined by Autism Impact Fund and Corundum Systems Biology (Tokyo, Japan). Existing investors, Longwood Fund, Seventure Partners, Taiho Ventures, and Domain Associates also participated in this round. The additional financing builds upon Axial’s earlier Series A and Series B financing rounds, bringing total investment in the company to $91.5 million to date.
Who to call at Axial Therapeutics, and when
A new round usually means Axial Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Axial Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Axial Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Axial Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Axial Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Axial Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.